Sanofi ends autoimmune disease drug development program with Nurix
Nurix said Sanofi has discontinued a development program for autoimmune and inflammatory diseases.
Related stories
Netflix Co-CEO Gregory Peters Sells $1.74 Million in Shares
Netflix shares slipped more than 1% overnight. The report cites a softer fourth-quarter revenue outlook, a reduced full-year advertising revenue forecast and slowing viewer-engagem
M impact | EQUITY | Nov 11, 2026, 04:53 AM UTC
IndiGo and Asian Paints Rise as Crude Slump Lifts Related Stocks
Shares of IndiGo, Asian Paints, Apollo Tyres and oil marketing companies rallied as Brent crude fell nearly 25% over 10 days. Global oil prices recovered modestly.
M impact | EQUITY | Nov 11, 2026, 04:52 AM UTC
Western Union Terminates Agreement to Acquire Intermex
M impact | EQUITY | Nov 11, 2026, 04:45 AM UTC
Nikkei Stock Average Rises 1.3% to 61252.50
M impact | EQUITY | Nov 11, 2026, 04:40 AM UTC
IIFL Finance shares extend gains, up 9.4%
M impact | EQUITY | Nov 11, 2026, 04:35 AM UTC
Reliance Industries shares rise 1.2%
L impact | EQUITY | Nov 11, 2026, 04:34 AM UTC